<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725123</url>
  </required_header>
  <id_info>
    <org_study_id>BEYOND1</org_study_id>
    <nct_id>NCT04725123</nct_id>
  </id_info>
  <brief_title>Addressing Personalized Needs in Clostridioides Difficile Infection</brief_title>
  <acronym>BEYOND</acronym>
  <official_title>Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection: Study Phase 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Institute for the Study of Sepsis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Institute for the Study of Sepsis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BEYOND is aiming to demonstrate how by enrichment of the available SPECIFY score, patients at&#xD;
      great likelihood for CDI with unfavorable outcome are early detected&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a previous project, following GWAS analysis of the DNA and measurement of serum biomarkers&#xD;
      coming from 134 patients a prediction score named SPECIFY was developed. The SPECIFY score&#xD;
      comprises four elements: low hemoglobin, increased urea, increased IL-8 and carriage of G&#xD;
      alleles of rs2091172. The score has 80% positive predictive value and 95.8% specificity for&#xD;
      the early detection of unfavorable outcome but the sensitivity is low. Unfavorable outcome is&#xD;
      defined as any of: presentation or progression into severe CDI, relapse; and death. Stool&#xD;
      samples of day 1 before start of therapy of the patients are stored refrigerated. Microbiome&#xD;
      analysis will be done aiming to the integration of the Shannon diversity index to the already&#xD;
      developed score in order to improve sensitivity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction of unfavorable outcome</measure>
    <time_frame>40 days</time_frame>
    <description>Sensitivity of the BEYOND score to predict unfavorable outcome of patients with infection by Clostridioides difficile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic PCR reaction in stool</measure>
    <time_frame>40 days</time_frame>
    <description>Development of one RT-PCR reaction informing of the predominance of bacterial generum causing low microbiome diversity associated with the unfavorable outcome of CDI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">153</enrollment>
  <condition>Clostridioides Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Clostridioides difficile infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stool of patients with Clostridioides difficile infection that will be subject to microbiome analysis. Comparisons will be done between patients with favorable and unfavorable outcome</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Microbiome analysis</intervention_name>
    <description>Stool microbiome analysis of 16S rRNA sequencing to an anticipated number of 8,000,000 reads</description>
    <arm_group_label>Clostridioides difficile infection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age more than or equal to 18 years&#xD;
&#xD;
          -  Both genders&#xD;
&#xD;
          -  Diarrhea defined as at least 3 episodes of unformed stools in the last 24hours&#xD;
             according to the Bristol stool chart&#xD;
&#xD;
          -  Presence of C.difficile in stool. This is defined as any stool sample positive for the&#xD;
             presence of glutamate dehydrogenase (GDH) and for the presence of toxin A and/or B.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ No exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evangelos J Giamarellos-Bourboulis, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evangelos J Giamarellos-Bourboulis, MD, PhD</last_name>
    <phone>00302105831000</phone>
    <phone_ext>994</phone_ext>
    <email>egiamarel@med.uoa.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asimina Safarika, MD, PhD</last_name>
    <phone>00302105831000</phone>
    <phone_ext>925</phone_ext>
    <email>asafarika@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>4th Department of Internal Medicine, ATTIKON University General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelos J Giamarellos-Bourboulis, MD, PhD</last_name>
      <phone>00302105831000</phone>
      <phone_ext>994</phone_ext>
      <email>egiamarel@med.uoa.gr</email>
    </contact>
    <contact_backup>
      <last_name>Georgia Damoraki, MD, PhD</last_name>
      <phone>00302105831000</phone>
      <phone_ext>994</phone_ext>
      <email>gdamoraki@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Evangelos J Giamarellos-Bourboulis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asimina Safarika, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridioides difficile</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Prediction</keyword>
  <keyword>Unfavorable outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared with other investigators after the end of the study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After the end of the study</ipd_time_frame>
    <ipd_access_criteria>Signed contract for data sharing with the study Sponsot</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

